Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

Impact · against what's priced in

Cullinan Therapeutics sees a positive catalyst from strong Phase 1 data for CLN-049, specifically the 31% CR/CRh rate in heavily pretreated AML patients and FDA Fast Track designation. The results demonstrate potential in high-risk TP53-mutated populations and a favorable safety profile, supporting the transition to expansion cohorts in 2026.

CGEM+0.70: No priced-in read yet

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

What matters in this story

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

What matters in this story

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

How each ticker is affected

Track these names every morning.

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

TRexBio Announces Pricing of Initial Public Offering

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

What matters in this story

Next reads from the same story arc

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

What matters in this story

Next reads from the same story arc

ROSEN, LEADING INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

How each ticker is affected

Track these names every morning.

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

Retension Pharmaceuticals Announces Pricing of Initial Public Offering

TRexBio Announces Pricing of Initial Public Offering